HemaSphere (May 2023)

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL

  • P. Rodríguez-Otero,
  • S. Ailawadhi,
  • B. Arnulf,
  • K. Patel,
  • M. Cavo,
  • A.K. Nooka,
  • S. Manier,
  • N. Callander,
  • L.J. Costa,
  • R. Vij,
  • N.J. Bahlis,
  • P. Moreau,
  • S.R. Solomon,
  • M. Delforge,
  • J. Berdeja,
  • A. Truppel-Hartmann,
  • Z. Yang,
  • L. Favre-Kontula,
  • F. Wu,
  • J. Piasecki,
  • M. Cook,
  • S. Giralt

DOI
https://doi.org/10.1097/01.HS9.0000936124.56965.24
Journal volume & issue
Vol. 7, no. S2
pp. 7 – 8

Abstract

Read online

No abstracts available.